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ABSTRACT 
Autoantibodies to glutamate decarboxylase (GADA) are sensitive markers of islet 
autoimmunity and type 1 diabetes. They form the basis of robust prediction models and are 
widely used for recruitment of subjects at high risk of type 1 diabetes to prevention trials. 
However GADA are also found in many individuals at low risk of diabetes progression. To 
identify the sources of diabetes irrelevant GADA reactivity therefore, we analyzed data from 
the 2009 and 2010 Diabetes Autoantibody Standardization Program GADA workshop and 
found that binding of healthy control sera varied according to assay type. Characterization of 
control sera found positive by radiobinding assay, but negative by ELISA showed that many 
of these sera reacted to epitopes in the N-terminal region of the molecule. This finding 
prompted development of an N-terminally truncated GAD65 radiolabel, 
35S-GAD65(96-585), 
which improved the performance of most GADA radiobinding assays (RBAs) participating in 
an Islet Autoantibody Standardization Program GADA substudy. These detailed workshop 
comparisons have identified a source of disease-irrelevant signals in GADA RBAs and 
suggest that N-terminally truncated GAD labels will enable more specific measurement of 
GADA in type 1 diabetes. 
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Accurate prediction of type 1 diabetes depends on islet autoantibody measurement. The 
presence of autoantibodies directed against multiple islet antigens confers a high risk of 
disease (1; 2), and improved performance of individual islet autoantibody assays would 
enable more efficient recruitment of high-risk subjects to therapeutic prevention trials. 
Autoantibodies to glutamate decarboxylase (GADA) are the most widely used marker for type 
1 diabetes, but to achieve optimum disease sensitivity the threshold for GADA positivity is 
often set at the 99th percentile, a level that exceeds the lifetime risk of developing the disease 
(3). Many individuals found GADA positive with current assays are therefore unlikely to 
progress to type 1 diabetes, making the development of more specific GADA assays a high 
priority (4). 
 
The Diabetes Antibody Standardization Program (DASP) was established in 2001 with the 
aim of improving islet autoantibody assay performance and concordance among laboratories 
(5). DASP has facilitated the rapid evaluation and adoption of novel autoantibody assays (6-8) 
and this work continues under the mantle of the Islet Autoantibody Standardization Program 
(IASP). During the lifetime of DASP/IASP there have been major improvements in assay 
performance and comparability, but the specificity of GADA assays can still vary by as much 
as 10% between laboratories that achieve similar sensitivity (9). 
 
Closer analysis of recent DASP/IASP workshops has revealed systematic differences in the 
reactivity of individual healthy control sera between ELISAs and radiobinding assays 
(RBAs). Several control sera showed increased binding of GAD65 in the majority of RBAs, 
despite being found negative in most ELISAs, while the converse was true for other control 
sera. We therefore investigated the binding characteristics of those control sera found positive 
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more commonly by RBA to identify sources of disease irrelevant signals and using this 
information, set out to develop more specific GADA assays.    
 
RESEARCH DESIGN AND METHODS 
DASP/IASP workshops 
Analysis was performed on samples included in the 2009 and 2010 DASP workshops as well 
as a GADA substudy in the 2012 IASP workshop (Supplemental Fig. 1). In each workshop, 
laboratories received uniquely coded sets of blinded sera from 50 patients with newly 
diagnosed type 1 diabetes contributed by several centers around the world, together with up to 
100 US blood donors without a family history of diabetes as healthy controls (Supplemental 
Table 1). Type 1 diabetes was diagnosed by local centers on the basis of clinical 
characteristics. All samples were collected within 14 days of starting insulin treatment. The 90 
control sera included in DASP 2010 were also among the 100 control sera used in DASP 
2009. Sera were prepared and frozen in 100 μL aliquots and distributed by the Centers for 
Disease Control and Prevention or University of Florida as previously described (10). 
Laboratories were asked to test samples for GADA using the assay formats of their choice, to 
provide details of their assay protocols, and to report assay results, including raw data, to 
DASP/IASP for analysis. Assays parameters varied between and within different formats. 
Major differences included the volume of serum used, buffer constituents, primary incubation 
time, separation method, washing technique and standardization method. To reduce variation 
between RBAs the standard method protocol was developed which fixed these aspects of the 
technique thereby allowing for greater comparability between laboratories (11). In the DASP 
2009 workshop, 42 laboratories from 19 countries reported results for 56 GADA assays. In 
the DASP 2010 workshop, 39 laboratories from 19 countries reported results for 53 GADA 
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assays. In the IASP 2012 workshop, 10 laboratories from 7 countries participated in a GADA 
substudy using non-commercial RBAs (Supplemental Appendix). 
  
Assessment of epitope specificities 
The epitope specificities of selected GADA workshop control sera were assessed using 
plasmids encoding full length GAD65, GAD67 and truncated GAD65, as well as GAD65-GAD67 
chimeras (12).  GAD67, GAD67(1-101)/GAD65(96-440)/GAD67(453-593), and GAD67(1-
243)/GAD65(235-444)/GAD67(453-593) were cloned into pGEM-Teasy (Promega), while 
GAD65(1-95)/GAD67(101-593) and GAD67(1-452)/GAD65(445-585) were cloned into pGEM3 
(Promega). GAD65(46-585) and GAD65(96-585) were cloned into pTnT (Promega). All 
plasmids were provided by Vito Lampasona apart from the pTNT plasmid pThGAD65 
encoding full length GAD65 (courtesy of Ake Lernmark). Samples were assayed for GADA 
using the standard assay protocol (11) with 35S-methionine labeled antigens made by in vitro 
transcription and translation of GAD65-GAD67 chimeras, truncated GAD65 and full-length 
GAD65. To further characterize GADA binding, selected DASP 2010 workshop sera were 
also assayed for GADA(1-585) and GADA(96-585) using the standard assay protocol with 
and without addition of 5 or 0.05 pmol per well of recombinant full-length GAD65 (Diamyd 
Medical AB, Stockholm, Sweden). Using this approach, median percentage displacement of 
GADA binding was calculated as 100*(cpm label alone – cpm label with unlabeled 
GAD)/cpm label alone) with a minimum set at 0%. Lack of displacement at 5 pmol/well 
would indicate a lack of specificity for GAD65, while lack of displacement at 0.05pmol/well 
would suggest that the antibodies were of low affinity, especially when levels of binding were 
low (13; 14).  
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For the IASP 2012 GADA substudy, participating laboratories generated 35S-labeled GAD 
using the pTnT plasmid (Promega, Madison, USA) vector encoding GAD65(96-585) 
distributed by Vito Lampasona, as well as their usual plasmid encoding full-length GAD65 or 
125I-labeled human recombinant full-length GAD65. Prior to the GADA substudy, coded 
DASP 2010 sets were assayed by three selected laboratories using both 35S-labeled 
GAD65(96-585) and GAD65(46-485) encoded in the same vector (Supplemental Figure 1). 
 
Data analysis 
Categorical variables were compared using the χ2 test. Areas under the curve (AUCs) for the 
different assays from receiver operator characteristics (ROC) analysis were compared using 
the Wilcoxon signed rank test. When laboratory assigned positive-negative calls were 
analyzed according to assay format, only those assays with specificity above 90% were 
included. For all analyses, a two-tailed P-value of 0.05 was considered significant. Statistical 
analyses were performed using the Statistics Package for Social Sciences Version 19 (IBM, 
New York, USA). 
 
RESULTS 
The pattern of GADA reactivity in healthy individuals is associated with assay format 
The median laboratory assigned sensitivities and specificities of GADA assays in the DASP 
2010 workshop were 86% (range 34 to 92%) and 94% (range 68 to 100%), respectively. 
According to threshold independent measures (10), adjusted sensitivity at 95% specificity 
(AS95) and AUC, the commercial ELISA showed the best overall performance (Figure 1). 
When assay results were analyzed according to assay format the positive-negative calls for 
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control sera often clustered according to assay type (Figure 2a). For example, control serum 
LQ21235 was scored positive by 8 of 10 laboratories using the commercial ELISA, but none 
of the other assays. In contrast, control sera N51532, N56575, N59932, S8531 and N53371 
were found positive by none of the laboratories using the commercial ELISA as compared to 
19 (54%), 18 (51%), 13 (37%), 10 (29%) and 10 (29%) of the other 35 assays, respectively. 
Another difference between assays was that serum N54357 was scored positive by 6 of 8 
RBAs using the commercial kit with iodinated GAD65 antigen, but none of the other 37 
assays. In contrast to the pattern observed in controls, no clear assay-specific differences in 
the reactivity of patient sera were seen (data not shown). 
 
Assays show a consistent pattern of reactivity over time 
The pattern of positive-negative calls for control sera in the DASP 2009 workshop was very 
similar to that of DASP 2010 (Figure 2b). The serum found positive exclusively by ELISA in 
DASP 2010, LQ21235, was positive in all 9 ELISAs, but none of the other assays. The five 
sera found positive by none of the laboratories using the commercial ELISA but at least 30% 
of other assays in DASP 2010, were again consistently negative by ELISA and positive in 20 
to 71 percent of other assays. Serum N54357 was positive in 6 of 11 commercial RBAs as 
well as the only other RBA using iodinated antigen, but in none of the other 38 assays. 
 
Characterization of control samples called positive in DASP 2010 
To determine whether the pattern of positivity in controls could be explained by differences in 
assay-specific reactivity to particular GADA epitopes, selected control samples were assayed 
by RBA using 35S labelled GAD65, GAD67 and GAD65/67 chimeras (12) (Figure 3). Of the 
three samples found positive more often by ELISA, LQ19277 showed dominant binding to 
the N-terminal of GAD67 and weak binding to full-length GAD65, while sera LQ21235 and 
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TS23727 recognized epitopes restricted to the N-terminal of GAD65 that were dependent on 
amino acids 46 to 95. However, as expected for a serum found positive exclusively by 
ELISA, LQ21235 showed very low levels of binding in these RBA experiments. Of the five 
control samples found positive more often by RBAs, three (N51532, N56575 and N59932) 
showed weak reactivity with the middle region of GAD65. A fourth serum (S8531), showed 
reactivity restricted to the N-terminal of GAD65.  The fifth serum, N53371, bound 
predominantly to epitopes in the N-terminal region of GAD65 with weaker responses to 
GAD67. 
Specificity of binding to 35S labelled GAD65(1-585) and GAD65(96-585) in these sera was 
confirmed by competitive displacement with excess (5 pmol per well) unlabeled GAD65. 
Median displacement of GADA binding in all 8 sera was 60% (range 39% to 78%) with 35S-
GAD65(1-585) and 72% (range 70% to 76%) in the three sera found positive with 
35S-
GAD65(96-585) (Supplemental Fig. 2a). This compares with a median displacement of 
binding in six GADA positive patients (IDS samples 004, 005, 006, 009, 097 and 195) of 87% 
(range 68% to 98%) and 91% (range 71% to 98%) for 35S-labeled GAD65(1-585) and 
GAD65(96-585), respectively (Supplemental Fig. 2b). 
To identify sera with low affinity antibodies, GADA binding was competed at a low 
concentration of unlabeled GAD65. Competition with 0.05 pmol per well unlabeled GAD65 
caused median displacement of binding by the six patient sera of 65% (range 40% to 86%) 
and 76% (range 61% to 87%) with 35S-labeled GAD65(1-585) and GAD65(96-585), 
respectively (Supplemental Fig. 2d). In contrast, median displacement of binding in the three 
sera showing weak reactivity with the middle region of GAD65 (N51532, N56575 and 
N59932) was 0% (range 0% to 15%) with 35S-labeled GAD65(1-585) and 14% (range 9 to 
24%) with 35S-labeled GAD65(96-585) indicating that these samples had low affinity 
antibodies (Supplemental Fig. 2c).      
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Evaluation of GADA assays using GAD65(46-585) and GAD65(96-585) plasmids 
To investigate whether replacing GAD65(1-585) with N-terminally truncated GAD65 
constructs could improve GADA assay performance, three laboratories assayed a new coded 
set of samples from DASP 2010 with 35S labels generated using plasmids encoding GAD65(1-
585), GAD65(46-585) and GAD65(96-585).  In each laboratory the highest AS95 (88%) was 
achieved using the GAD65(96-585) construct (Supplemental Fig. 3). 
  
Evaluation of GAD65(96-585) in the IASP 2012 GADA substudy 
The potential of the GAD65(96-585) radiolabel to improve the performance of GADA RBAs 
was assessed by 10 laboratories in the IASP 2012 GADA substudy.  Participating laboratories 
assayed coded IASP sets using both 35S or 125I labelled GAD65(1-585) and 
35S labelled 
GAD65(96-585). Of the 10 laboratories, 8 showed higher AS95 values with GAD65(96-585) 
(Figure 4). Changes in the AS95 with the GAD65(96-585) label ranged widely from -14 to 
+20%, showing that even within RBAs the reactivity of different sera is strongly influenced 
by local assay conditions.  
 
DISCUSSION 
Using data from DASP workshops we have shown that the binding of GAD65 by healthy 
control sera segregated according to assay format. Some control sera reacted preferentially in 
the commercial ELISA but not in the RBA, while others found positive in many RBAs 
showed no binding in ELISAs.  A high proportion of the control sera found positive by RBAs 
targeted epitopes in the N-terminal region of GAD65 which are less commonly recognized by 
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diabetes-relevant antibodies (15-18). These findings prompted the construction of a plasmid 
encoding GAD65(96-585), suitable for generating N-terminally truncated radiolabel. In the 
IASP 2012 GADA substudy, 8 of 10 RBAs using this plasmid achieved a higher adjusted 
sensitivity than those using full-length GAD65, indicating that the performance of many RBAs 
could be improved by use of N-terminally truncated GAD radiolabels. 
 
Earlier islet autoantibody workshops have shown differences in assay performance that could 
be ascribed to particular characteristics. The higher sensitivity of IA-2 autoantibody assays 
using plasmids expressing the intracellular region (ic) rather than the IA-2(256–556/630–979) 
or full-length constructs led to more widespread adoption of IA-2ic autoantibody assays (10). 
The clear superiority of RBAs over ELISAs for measuring insulin autoantibodies (IAA) has 
meant that RBAs have been used almost exclusively for IAA measurement (19). The 
differences we observed with GADA assay format were more subtle, but by focusing on 
signals generated by healthy control sera, we were able to identify an important source of 
disease irrelevant signals in the N-terminus affecting RBAs. Despite the superior overall 
performance of the GADA ELISA, analogous modification of the capture antigen in the 
ELISA format may improve the specificity of the assay. Even in the most robust GADA 
ELISAs, false positive signals from sera acquired from healthy individuals contribute 
significantly to the higher background levels of binding that define assay thresholds, limiting 
our ability to assign true beta-cell autoimmunity. 
 
Birth cohort prospective studies of relatives of patients with type 1 diabetes have shown that 
diabetes relevant autoantibody epitope reactivity typically spreads from the C-terminal and 
middle (PLP) regions to the N-terminal domains of the molecule (12; 16). Autoantibodies to 
11 
 
the N-terminal region typically constitute a relatively minor component of GAD65 
autoreactivity and alone confer little association with type 1 diabetes (17). However, we 
cannot exclude the possibility that a very small proportion of sera from patients with type 1 
diabetes may bind exclusively to the N-terminus and will be missed by the truncated antigen. 
Furthermore, in patients with other forms of diabetes such as latent autoimmune diabetes in 
adults or slowly progressive type 1 diabetes mellitus, epitopes in the N-terminal region may 
constitute a larger proportion of the anti-GAD response (20; 21). The potential benefit of 
using truncated antigen to test for these conditions therefore, needs to be evaluated. Cross-
reactive N-terminal restricted GADA may mark an early phase of autoimmunity in 
neurological conditions such as Stiff Person Syndrome (SPS) (22-24), although as those 
disorders are rare and SPS itself is associated with very high GADA titers (25), the low level 
N-terminal restricted antibodies found in healthy controls are  more likely attributed to cross-
reactivity of irrelevant antibodies.   
 
The commercial ELISA showed good sensitivity and specificity in DASP and IASP 
workshops (9). This assay relies on the autoantibody forming a bridge between immobilized 
GAD65 on the plate and biotinylated GAD65 in solution with detection by streptavidin 
peroxidase (26). Access to N-terminal epitopes may be hindered in this configuration 
preventing the binding of the N-terminally restricted antibodies detected by many RBAs. This 
could also partly explain why luminescence immunoprecipitation (LIPS) and 
electrochemiluminescence (ECL) assays (27; 28), showed good specificity in recent 
workshops. However, we cannot exclude that other mechanisms may be responsible for lack 
of binding of these N-terminally restricted control sera in the ELISA. Some of the assay-
dependent differences in recognition of DASP/IASP control sera are likely to be related to 
antibody affinity. The three control sera found reactive with the middle region of GAD in 
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RBAs, but negative by ELISA showed minimal displacement at low levels of competing 
GAD65 which suggests that these sera contain low affinity antibodies. This may be why these 
antibodies were not detected by the commercial ELISA or the ECL assay, as the bridging 
format they employ favors the recognition of  high affinity antibodies, which are more closely 
associated with diabetes progression (17; 29). The performance of RBAs using N-terminally 
truncated GAD65 labels may therefore be further improved by including affinity 
measurements. 
 
A major strength of this study was the availability of data from a number of DASP and IASP 
workshops which allowed us to identify consistent patterns in the reactivity of control sera 
according to assay format. The original design of the DASP workshops (10), with the 
inclusion of a relatively large number of control sera, has again been vindicated, as it allowed 
us to identify systematic differences in reactivity which would have been impossible with a 
smaller number of samples. These sample sets distributed to laboratories are however still 
limited with regard to sample number, as well as ethnicity, age and their cross-sectional 
nature. Other important systematic variations in GADA binding by healthy control sera may 
be identified in different cohorts. Furthermore, only 10 laboratories participated fully in the 
IASP 2012 GADA substudy, which restricted our ability to determine whether use of the 
GAD65(96-585) label could enhance assay performance.  
 
Measurement of GADA is fundamental to most strategies aimed at prediction and 
characterization of type 1 diabetes, but there has been concern that despite their high 
sensitivity GADA are often less closely associated with diabetes progression than other islet 
autoantibodies such as IA-2A and ZnT8A (30). The DASP and IASP workshops have 
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revealed assay-related differences in binding of GAD65 by control sera that should aid the 
development of more specific GADA assays. If the promise shown by the N-terminally 
truncated GAD65(96-585) antigen probe to improve the specificity of GADA RBAs without 
loss of sensitivity is confirmed in large prospective studies, we would advocate its adoption 
for population screening in combination with other islet autoantibodies to identify individuals 
at high risk of progression to type 1 diabetes. 
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 Figure legends 
Figure 1. Adjusted sensitivity at 95% specificity (AS95) plotted against the area under the 
curve (AUC) from ROC analysis of GADA assays participating in the DASP 2010 workshop. 
Using these threshold independent measures, better performance is demonstrated by those 
assays located towards the top right hand corner (circled), a cluster that includes all the 
commercial ELISAs.   
 
Figure 2. Heatmaps of laboratory defined positive-negative calls for (a) the 10 healthy control 
sera found positive most often in DASP 2010 and (b) the same sera in DASP 2009 for those 
assays with a laboratory defined specificity of more than 90% sorted according to assay type. 
Positive-negative calls were found to cluster according to assay type; sera shaded in blue were 
found positive most commonly by commercial ELISAs, those in yellow by RBAs and the 
serum shaded in orange by RBAs using 125I-labeled GAD65. 
 
Figure 3. Epitope specificity of 8 healthy control sera from the DASP 2010 workshop that 
showed assay-related differences in reactivity. The left panel shows the different GAD 
constructs used to assess epitope specificity with regions derived from GAD65 in black and 
GAD67 in white. The right panel shows reactivity of the control sera with these GAD 
constructs and the epitope reactivity ascribed to those sera based on the pattern of binding 
with the different constructs. Four sera (S8531, N53371, TS23727, and LQ21235) showed 
reactivity with GAD65 N-terminal epitopes that was abolished by deletion of the first 95 
amino acids. Three control sera (N56575, N51532 and N59932) showed weak reactivity with 
the MID region of GAD65 (aa 235-444) and this binding was not reduced by use of the N-
terminally truncated labels. 
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Figure 4. AS95 for ten RBAs using 35S or 125I-GAD65 (1-585) and 
35S-GAD65(96-585) to 
measure workshop samples in the IASP 2012 GADA substudy. Improved performance of 
assays using the N-terminally truncated GAD is shown by the 8 laboratories that lie above the 
line of equivalence (hatched line). 
 
